The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
New generation of mucosal adjuvants for the induction of protective immunity
Abstract
Invasion of infectious agents through mucosal surfaces can be prevented by use of the common mucosal immune system (CMIS), which interconnects inductive tissues, including Peyer's patches (PPs) and nasopharyngeal‐associated lymphoreticular tissue (NALT), and effector tissues of the intestinal and respiratory tracts. In order for the CMIS to induce maximal protective mucosal immunity, co‐administration of mucosal adjuvant has been shown to be essential. When vaccine antigen is administered together with mucosal adjuvant, antigen‐specific T‐helper (Th) 1 and Th2 cells, cytotoxic T lymphocytes (CTLs) and IgA B cell responses are effectively induced by oral or nasal routes via the CMIS. In the early stages of induction of mucosal immune response, the uptake of orally or nasally administered antigens is achieved through a unique set of antigen‐sampling cells, M cells located in follicle‐associated epithelium (FAE) of inductive sites. After successful uptake, the antigens are immediately processed and presented by the underlying dendritic cells (DCs). Elucidation of the molecular/cellular characteristics of M cells and mucosal DCs will greatly facilitate the design of a new generation of effective mucosal adjuvants and of a vaccine delivery vehicle that maximises the use of the CMIS. Our recent efforts at mucosal vaccine development have focused on nasal administration of vaccine antigen together with nontoxic mutant‐based or cytokine‐/chemokine‐based adjuvant for the induction of the protective immunity. To this end, a chimeric form of a nontoxic adjuvant combining the merits of mutant cholera toxin A subunit (mCT‐A) and heat labile toxin B subunit (LT‐B) was created as the second generation of detoxified toxin‐based mucosal adjuvant. When a vaccine antigen was coexpressed together with an immune stimulatory/delivery molecule in crop seed, this edible vaccine is not only effective but also extremely practical in that it can be produced in huge quantities and preserved and shipped over long distances at room temperature without altering the quality of the vaccine. Because such qualities would greatly facilitate global vaccination, this new generation edible vaccines with a built‐in adjuvant and/or M cell‐targeted edible vaccine promises to be a powerful weapon for combating infectious diseases and bioterrorism. Copyright © 2003 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 2×
“Because TLR9-knockout mice are completely defective in their responses to CpG, failing to exhibit cytokine production by macrophages, B cell proliferation and the maturation of DCs, it can be surmised that TLR9 plays an essential role in immunological responses to CpG [40].”
Toll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777
Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells
Rincón, M., Anguita, J., Nakamura, T., Fikrig, E., & Flavell, R. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.3.461 · Cited by 810
Cited by
Solid lipid nanoparticles as a drug delivery system for peptides and proteins☆
ALMEIDA, A., & SOUTO, E. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.007 · Cited by 814
NALT- versus PEYER'S-patch-mediated mucosal immunity
Kiyono, H., & Fukuyama, S. (2004) · Nature Reviews Immunology · doi:10.1038/nri1439 · Cited by 745
Self-citationNanomaterial Delivery Systems for mRNA Vaccines
Buschmann, M. D., Carrasco, M. J., Alishetty, S., Paige, M., Alameh, M. G., & Weissman, D. (2021) · Vaccines · doi:10.3390/vaccines9010065 · Cited by 582
Nanoparticles: Emerging carriers for drug delivery
Mudshinge, S. R., Deore, A. B., Patil, S., & Bhalgat, C. M. (2011) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2011.04.001 · Cited by 543
Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines
Nochi, T., Yuki, Y., Takahashi, H., Sawada, S.-I., Mejima, M., Kohda, T., Harada, N., Kong, I. G., Sato, A., Kataoka, N., et al. (2010) · Nature Materials · doi:10.1038/nmat2784 · Cited by 468
Self-citationMitragotri, S. (2005) · Nature Reviews Immunology · doi:10.1038/nri1728 · Cited by 395
Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination
Nochi, T., Takagi, H., Yuki, Y., Yang, L., Masumura, T., Mejima, M., Nakanishi, U., Matsumura, A., Uozumi, A., Hiroi, T., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703766104 · Cited by 335
Self-citationKim, D.-Y., Sato, A., Fukuyama, S., Sagara, H., Nagatake, T., Kong, I. G., Goda, K., Nochi, T., Kunisawa, J., Sato, S., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903794 · Cited by 115
Self-citation
Metadata
- Authors
- Yuki, Y., & Kiyono, H.
- Venue
- Reviews in Medical Virology
- Publisher
- Wiley
- Published
- 2003-08-15
- Volume
- 13
- Issue
- 5
- Pages
- 293-310
- ISSN
- 1052-9276 (ISSN-L)
- 1099-1654
- OpenAlex
- W2017690097
- Cited by
- 191
- References
- 3
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.